Pfizer Inc. — Wall Street Analyst Estimates & Price Targets

PFE

NYSEHealthcareDrug Manufacturers - GeneralCIK 0000078003pfizer.comAbout PFE

Last close · Oct 16, 202629.58+0.14 (+0.48%)

Market cap$168.6B

4 firms' latest targets, last 90 days: median $30.50 ($28.00–$33.00), 3% above the last close.

Price and published targets

daily close, 12 months · each dot a target, a firm's latest darker

Each firm's latest target

last 90 days · 4 firms

Date	Firm	Target	Previous	Change	Vs price then	Vs price now
2026-10-08	Cantor Fitzgerald	$28.00	$27.00	▲ 4%	+0%	-5%
2026-10-06	Scotiabank	$33.00	—	—	+21%	+12%
2026-09-10	HSBC	$30.00	$28.00	▲ 7%	+8%	+1%
2026-08-07	Guggenheim	$31.00	$35.00	▼ 11%	+18%	+5%

Consensus estimates

revenue and EPS by fiscal year · reported years marked

FY	Revenue	YoY	EPS	YoY	Revenue range	EPS range	Analysts
2023reported	$50.9B	-45%	$0.37	-93%	est. $58.8B-13%	est. $1.55	10
2024reported	$63.6B	+25%	$1.41	+281%	est. $63.1B+1%	est. $2.93	14
2025reported	$62.6B	-2%	$1.36	-4%	est. $61.9B+1%	est. $3.12	13
2026	$62.2B	-1%	$2.96	-5%	$61.3B–$63.0B	$2.89–$3.03	18
2027	$59.8B	-4%	$2.90	-2%	$58.2B–$61.1B	$2.79–$3.10	17
2028	$54.8B	-8%	$2.49	-14%	$50.9B–$58.1B	$1.61–$3.03	22
2029	$53.0B	-3%	$2.36	-5%	$51.6B–$54.6B	$2.28–$2.46	14
2030	$53.4B	+1%	$2.45	+4%	$51.9B–$55.0B	$2.36–$2.54	11

A reported year shows the company's figures, with the consensus beside it (revenue against it in %). Reported EPS is GAAP diluted; the analysts' EPS usually leaves items such as stock compensation out, so the two are not like for like. Faded: a year the valuation models do not read — they read the first 3, and a later one only while 10 or more analysts cover every year up to it — or one under 5 analysts.

The analysts at a glance

$30.50median target, 3% above the last close

Firms with a target · last 90 days: 4
Lowest – highest target: $28.00 – $33.00
Current grades of 13 firms: positive / neutral / negative: 5 / 8 / 0
Upgrades / downgrades · 12 months: 2 / 1
Consensus revenue growth · next 3 FY: -4% a year

Current grades

each firm's latest · 13 firms

As of	Firm	Grade
2026-10-09	J.P. Morgan	“Neutral”
2026-10-08	Cantor Fitzgerald	“Neutral”
2026-10-06	Scotiabank	“Sector Outperform”
2026-09-10	HSBC	“Hold”
2026-08-07	Guggenheim	“Buy”
2026-07-13	BMO Capital	“Outperform”
2026-07-10	Bank of America	“Neutral”
2026-06-10	RBC Capital	“Sector Perform”
2026-04-29	Citigroup	“Neutral”
2026-04-13	UBS	“Neutral”

3 more

2026-04-10	Morgan Stanley	“Equal Weight”
2026-03-02	Argus Research	“Buy”
2026-02-09	Freedom Capital Markets	“Buy”

Grade changes

last 24 months · 4

Date	Firm	Grade
2026-07-06	HSBC	“Buy” → “Hold” downgrade
2026-06-10	RBC Capital	“Underperform” → “Sector Perform” upgrade
2026-03-02	Argus Research	“Hold” → “Buy” upgrade
2025-04-08	Goldman Sachs	“Buy” → “Neutral” downgrade

47 older than 24 months

2024-08-08	Daiwa Capital	“Neutral” → “Outperform” upgrade
2024-03-22	Argus Research	“Buy” → “Hold” downgrade
2024-01-04	TD Cowen	“Outperform” → “Market Perform” downgrade
2023-10-16	Jefferies	“Hold” → “Buy” upgrade
2023-06-29	Credit Suisse	“Outperform” → “Neutral” downgrade
2023-05-11	Daiwa Capital	“Outperform” → “Neutral” downgrade
2023-02-07	Daiwa Capital	“Neutral” → “Outperform” upgrade
2023-01-26	UBS	“Buy” → “Neutral” downgrade
2023-01-17	Wells Fargo	“Overweight” → “Equal Weight” downgrade
2023-01-04	Bank of America	“Buy” → “Neutral” downgrade
2022-12-13	Goldman Sachs	“Neutral” → “Buy” upgrade
2022-01-05	Bank of America	“Neutral” → “Buy” upgrade
2021-12-13	UBS	“Neutral” → “Buy” upgrade
2021-05-06	Mizuho	“Buy” → “Neutral” downgrade
2021-02-04	DZ Bank	“Hold” → “Buy” upgrade
2020-12-16	RBC Capital	“Outperform” → “Sector Perform” downgrade
2020-11-10	Bernstein	“Market Perform” → “Perform” revised
2020-10-12	Atlantic Equities	“Overweight” → “Neutral” downgrade
2020-06-16	Leerink Partners	“Market Perform” → “Perform” revised
2019-08-28	DZ Bank	“Sell” → “Hold” upgrade
2019-07-30	Bank of America	“Buy” → “Neutral” downgrade
2019-07-30	Morgan Stanley	“Overweight” → “Equal Weight” downgrade
2019-01-31	Argus Research	“Neutral” → “Outperform” upgrade
2019-01-31	Credit Suisse	“Neutral” → “Outperform” upgrade
2019-01-23	UBS	“Buy” → “Neutral” downgrade
2018-12-11	J.P. Morgan	“Overweight” → “Neutral” downgrade
2018-11-01	BMO Capital	“Outperform” → “Market Perform” downgrade
2018-04-05	Barclays	“Overweight” → “Equal Weight” downgrade
2017-09-20	Morgan Stanley	“Equal Weight” → “Overweight” upgrade
2017-08-02	BMO Capital	“Market Perform” → “Outperform” upgrade
2017-07-20	Credit Suisse	“Outperform” → “Neutral” downgrade
2017-05-16	Citigroup	“Neutral” → “Sell” downgrade
2016-11-29	Barclays	“Equal Weight” → “Overweight” upgrade
2016-11-02	Argus Research	“Buy” → “Hold” downgrade
2016-11-02	BMO Capital	“Outperform” → “Market Perform” downgrade
2016-10-13	Jefferies	“Buy” → “Hold” downgrade
2015-11-25	Truist	“Reduce” → “Neutral” upgrade
2015-10-20	TD Cowen	“Market Perform” → “Outperform” upgrade
2015-10-02	Morgan Stanley	“Equal Weight” → “Overweight” upgrade
2015-02-09	BMO Capital	“Market Perform” → “Outperform” upgrade
2014-07-28	BMO Capital	“Outperform” → “Market Perform” downgrade
2014-02-04	Jefferies	“Hold” → “Buy” upgrade
2014-01-10	TD Cowen	“Outperform” → “Market Perform” downgrade
2013-11-14	LBBW Research	“Hold” → “Buy” upgrade
2013-07-12	Jefferies	“Buy” → “Hold” downgrade
2013-07-02	Standpoint Research	“Hold” → “Sell” downgrade
2012-11-27	MKM Partners	“Buy” → “Neutral” downgrade

Targets, grades and estimates are quoted from third parties (via Financial Modeling Prep) and are theirs, not ours; each target links to the report it was published in. A firm counts once, at its latest target or grade.